Please provide your email address to receive an email when new articles are posted on . A greater proportion of participants in the twice-daily pilocarpine HCl group had near-vision improvements. The ...

The purpose of this study was to evaluate the unstimulated whole-salivary biochemical composition in cGVHD patients before and after the administration of oral pilocarpine. Twenty-eight patients with ...

Pilocarpine hydrochloride has been reported to increase salivation and decrease oral mucositis in patients receiving head and neck radiotherapy, but there is only one report of its use in a cancer ...

Please provide your email address to receive an email when new articles are posted on . CSF-1 0.4% pilocarpine drops for presbyopia showed promising outcomes in phase 3 trials. The drops were well ...

Researchers estimate that about 1.8 billion people around the world live with presbyopia, a farsightedness condition that can appear as a person grows older. More recent treatment options for ...

- Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects and affects nearly half of the U.S. adult population, ...

The FDA approved pilocarpine hydrochloride ophthalmic solution (Qlosi) for adults with presbyopia, according to a statement from Orasis Pharmaceuticals. The approval allows for daily or as-needed use, ...

QLOSI™ is a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials Affecting more than 128 million people ...